Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia
Open Access
- 14 July 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in Blood Cancer Journal
- Vol. 7 (7), e583
- https://doi.org/10.1038/bcj.2017.62
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Frequency of rare BCR‐ABL1 fusion transcripts in chronic myeloid leukemia patientsInternational Journal of Laboratory Hematology, 2016
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitorsBlood, 2016
- Prognostic Impact of p190 and p210 Co-Expression at Diagnosis in Chronic Myeloid Leukemia (CML) Patients Treated with ImatinibBlood, 2014
- Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinibHaematologica, 2014
- A multiplex PCR for improved detection of typical and atypical BCR–ABL fusion transcriptsLeukemia Research, 2008
- Lymphoid preponderance and the absence of basophilia and splenomegaly are frequent in m-bcr-positive chronic myelogenous leukemiaAnnals of Hematology, 2002
- Chronic Myelogenous Leukemia with p190BCR-ABL Expression: The Missing Link with MonocytosisInternal Medicine, 2002
- Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Expressing p190BCR-ABL.Internal Medicine, 2002
- The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemiaEuropean Journal of Cancer, 2000